Clinical Nuclear Medicine

Article	Citations
Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers	85
Fibroblast Activation Protein Inhibitor PET/CT	73
Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer	56
Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT	55
Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04	53
Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET	48
Fully Automated Gross Tumor Volume Delineation From PET in Head and Neck Cancer Using Deep Learning Algorithms	44
Theranostic Approach in Breast Cancer	44
COVID-19 mRNA Vaccination–Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT	39
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells	36
99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer	35
177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme	35
Decentralized Distributed Multi-institutional PET Image Segmentation Using a Federated Deep Learning Framework	35
Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT	34
Increased 68Ga-FAPI Uptake in Chronic Cholecystitis and Degenerative Osteophyte	33
Two Tumors, One Target	31
Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI	29
18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer	29
Feasibility of Deep Learning-Guided Attenuation and Scatter Correction of Whole-Body 68Ga-PSMA PET Studies in the Image Domain	28
FAPI Uptake in a Vertebral Body Fracture in a Patient With Lung Cancer	26
68Ga-FAPI PET/CT in Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy	26
Inflammatory Arthritis Induced by Anti-Programmed Death-1 Shown in 68Ga-FAPI PET/CT in a Patient With Esophageal Carcinoma	25
68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient With Neuroendocrine Tumor	25
Uterine Uptake of 68Ga-FAPI-04 in Uterine Pathology and Physiology	24
Increased FAPI Uptake in Brain Metastasis From Lung Cancer on 68Ga-FAPI PET/CT	24

The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination	24
COVID-19 Vaccination–Associated Lymphadenopathy on FDG PET/CT	23
68Ga-FAPI Uptake of Thyroiditis in a Patient With Breast Cancer	23
Elevated 68Ga-FAPI Activity in Splenic Hemangioma and Pneumonia	23
177Lu-FAPI Therapy in a Patient With End-Stage Metastatic Pancreatic Adenocarcinoma	23
Hybrid PET/MRI in Staging Endometrial Cancer	23
FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177Lu-FAPI-46	23
Organizing Pneumonia With Intense 68Ga-FAPI Uptake Mimicking Lung Cancer on 68Ga-FAPI PET/CT	22
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases	22
Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT	21
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors	21
First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer	21
Fibroblast Activation Protein–Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT	21
The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors	21
Increased 68Ga-FAPI-04 Uptake in Schmorl Node in a Patient With Gastric Cancer	20
18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT Findings of Bilateral Knee Osteoarthritis in a Patient With Uveal Malignant Melanoma	20
COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT	20
Potential and Most Relevant Applications of Total Body PET/CT Imaging	20
Novel Experience in Hybrid Tracers	20
68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer	19
The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer	19
Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer	19
Intense Diffuse Uptake of 68Ga-FAPI-04 in the Breasts Found by PET/CT in a Patient With Advanced Nasopharyngeal Carcinoma	19
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors	18
Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor	18
Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System	18
False-Positive 68Ga–Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer	18
Performance Evaluation of a Deep Learning System for Differential Diagnosis of Lung Cancer With Conventional CT and FDG PET/CT Using Transfer Learning and Metadata	17
Primary Central Nervous System Lymphoma Revealed by 68Ga-FAPI and 18F-FDG PET/CT	17
Safety and Efficacy of 68Ga- or 177Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases	17
Idiopathic Retroperitoneal Fibrosis With Intense Uptake of 68Ga-Fibroblast Activation Protein Inhibitor and 18F-FDG	17
68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for the Evaluation of Disease Activity in Takayasu Arteritis	16
First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer	16
68Ga-DOTA-FAPI-04 PET/CT in Erdheim-Chester Disease	16
Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma	16
Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer	16
Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT	16
68Ga-FAPI PET/CT Distinguishes the Reactive Lymph Nodes From Tumor Metastatic Lymph Nodes in a Patient With Nasopharyngeal Carcinoma	16
Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms	16
68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients	16
COVID-19 Vaccine–Related Local FDG Uptake	16
68Ga-FAPI and 18F-PET/CT Images in Intestinal Tuberculosis	15
Chatbots in Medical Research	15
18F-THK5351 PET Can Identify Core Lesions in Different Amyotrophic Lateral Sclerosis Phenotypes	15
Bone Tuberculous Granulomatous Inflammation Mimicking Malignancy on 68Ga-FAPI PET/CT	15
68Ga-FAPI-04 PET/CT Imaging for Fibrous Dysplasia of the Bone	15
Differentiation of Reactive Lymph Nodes and Tumor Metastatic Lymph Nodes With 68Ga-FAPI PET/CT in a Patient With Squamous Cell Lung Cancer	14
68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma	14
The Search for New 2-18F-FDG PET/CT Imaging Biomarkers in Advanced Ovarian Cancer Patients	14
Usefulness of 68Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome	14

Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors	14
Response to Treatment in IgG4-Related Disease Assessed by Quantitative PET/CT Scan	14
Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination	14
Bone Uptake in Prostate Cancer Patients	14
Increased 68Ga-FAPI Uptake in Ankylosing Spondylitis in a Patient With Rectal Cancer	14
68Ga-DOTA-FAPI-04 PET/CT in Neuroendocrine Carcinoma of the Liver With Elevated AFP Level	14
The Concept of Strength Through Synergy Applied to the Search of Powerful Prognostic Biomarkers in Gastroesophageal Cancer	13
Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma	13
Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication	13
Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer	13
68Ga-FAPI-04 PET/CT in Selected Breast Cancer Patients With Low FDG Affinity	13
False-Positive Axillary Lymph Nodes on FDG PET/CT Resulting From COVID-19 Immunization	13
18F-FDG–Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT	13
Vaccine-Related Lymph Nodes	13
Immunoglobulin G4–Related Sclerosing Cholangitis Revealed by 68Ga-FAPI PET/MR	12
Comparison of 18F-FDG and 68Ga-FAPI-04 Uptake in Postoperative Re-evaluation of Gastric, Duodenal, and Colorectal Cancers	12
Chemokine Receptor 4–Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma	12
Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson’s Disease, Parkinson-Plus Syndrome, and Essential Tremor	12
Evaluation of the Hybrid Tracer Indocyanine Green–99mTc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer—A Prospective Pilot Study	12
Solitary Fibrous Tumors of the Pleura Shown on 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT	12
Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging	12
Intense 68Ga-FAPI Uptake in a Patient With Myositis Ossificans	12
FDG PET/MRI of Acute Myocarditis After mRNA COVID-19 Vaccination	12
Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab	12
18F-MFBG PET/CT Is an Effective Alternative of 68Ga-DOTATATE PET/CT in the Evaluation of Metastatic Pheochromocytoma and Paraganglioma	12
PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE	12
The Detection Performance of 18F–Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer	12
New Horizons in Radioligand Therapy	12
Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging	12
Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination	12
Lymphoscintigraphic Findings as Indicators of Lymphaticovenous Anastomosis Outcome in Patients With Extremity Lymphedema	12
Prognostic Value of Interim 18F-DOPA and 18F-FDG PET/CT Findings in Stage 3–4 Pediatric Neuroblastoma	12
FDG PET/CT and MRI Features of Pathologically Proven Schwannomas	12
Increased 68Ga-FAPI Uptake in Neurofibromatosis in a Patient With Pleomorphic Rhabdomyosarcoma	11
68Ga-FAPI PET/CT Detected Non–PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer	11
Increased 68Ga-FAPI Uptake in the Pulmonary Cryptococcus and the Postradiotherapy Inflammation	11
Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma	11
Benign Bone Cyst Mimicking Bone Metastasis Demonstrated on 68Ga-FAPI	11
Systemic Vasculitis Following SARS-CoV-2 mRNA Vaccination Demonstrated on FDG PET/CT	11
Similar Findings on 18F-MFBG PET/CT and 68Ga-DOTATATE PET/CT in a Patient With Widespread Metastatic Pheochromocytoma	11
Histopathological Features of Parathyroid Adenoma and 18F-Choline Uptake in PET/MR of Primary Hyperparathyroidism	11
Visualization of Motor Cortex Involvement by 18F-THK5351 PET Potentially Strengthens Diagnosis of Amyotrophic Lateral Sclerosis	11
Pleural Metastasis of Papillary Thyroid Cancer Depicted by 68Ga-FAPI PET/CT	11
FDG PET Findings Post–COVID Vaccinations	11
JAK Inhibitor Effectiveness in Giant-Cell Arteritis With Large-Vessel Involvement Assessed by 18F-FDG PET-CT	11
68Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression	11
Use of 68Ga-FAPI PET/CT for Detecting Myeloid Sarcoma of the Breast and Assessing Early Response to Chemotherapy	11
68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in Malignant Peritoneal Mesothelioma	11
Sentinel Lymph Node Biopsy in Prostate Cancer Using the SENSEI® Drop-In Gamma Probe	11
225Ac-DOTATOC–Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation	11
New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms	11
Prognostic Significance of Pretreatment 18F-FDG PET/CT Volumetric Parameters in Patients With Colorectal Liver Metastasis	11
Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery	11
Lymph Node Assessment in Prostate Cancer	10
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy	10
Uncommon Metastases From Occult Breast Cancer Revealed by 18F-FDG and 68Ga-FAPI PET/CT	10
PET Imaging of Dementia	10
68Ga–Prostate-Specific Membrane Antigen PET/CT Uptake in Intraventricular Meningioma in the Choroid Plexus	10
Comparison of 18F-PSMA-1007 PET/CT With 68Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer	10
Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis on 68Ga-FAPI-04 and 18F-FDG PET/CT	10
Short-Interval, Low-Dose [177Lu]Lu–Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma	10
Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer	10
225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer	10
89Zr-PSMA-617 PET/CT May Reveal Local Recurrence of Prostate Cancer Unidentified by 68Ga-PSMA-11 PET/CT	10
68Ga-FAPI and 18F-FDG PET/CT Findings in a Patient With Pancreatic Tuberculosis Mimicking Malignant Tumor	10
Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging	10
Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm	10
Increased 18F-ALF-NOTA-FAPI and 18F-FDG Uptake in Renal Angiomyolipoma	9
Biodistribution and Internal Dosimetry of 68Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases	9
Recurrent Glioma	9
Intense 68Ga-FAPI-46 Activity in Lesions of Recurrent Ovarian Clear Cell Carcinoma That Were Negative on FDG PET/CT Study	9
68Ga-FAPI-04 PET/CT in a Small Sarcomatoid Renal Cell Carcinoma With Widespread Metastases	9
18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer	9
Diagnostic Test Accuracy of 18F-FDG PET or PET/CT for Characterization of Histologic Type of Thymic Epithelial Tumor	9
Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies	9
Quantitative Features From CHO PET Distinguish the WHO Grades of Primary Diffuse Glioma	9
The Role of 68Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up	9
68Ga-FAPI PET/CT Imaging of Graves Ophthalmopathy in a Patient With Esophageal Cancer	9
Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers	9
68Ga-DOTA-FAPI-04 PET/CT Imaging in a Case of SAPHO Syndrome	9

Role of 68Ga-FAPI PET/CT in Assessing Hepatobiliary Malignancies	9
Hepatic Lesion of Mucosa-Associated Lymphoid Tissue Lymphoma Revealed by Al18F-NOTA-FAPI-04 PET/CT	9
Positive Correlation Between 18F-FDG Uptake and Tumor-Proliferating Antigen Ki-67 Expression in Adrenocortical Carcinomas	9
Systemic Immune Response Syndrome After COVID-19 Immunization—Initial and Follow-up 18F-FDG PET/CT Imaging Appearances	9
Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma	9
Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain	9
68Ga-DOTATOC PET/CT in Pleural Solitary Fibrous Tumors	8
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors	8
Aortitis PET Imaging in VEXAS Syndrome	8
Prognostic Impact of Metabolic Heterogeneity in Patients With Newly Diagnosed Multiple Myeloma Using 18F-FDG PET/CT	8
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics	8
Esophagitis Mimicking Esophageal Cancer on 68Ga-FAPI PET/CT	8
177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple Metastatic Lesions	8
18F-Fluciclovine–Avid Reactive Axillary Lymph Nodes After COVID-19 Vaccination	8
Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy	8
Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain	8
68Ga-DOTATATE Uptake in Primary Breast Cancer	8
68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma	8
Positive FAPI PET/CT in a Bilateral Mammary Angiosarcoma Patient With Less Impressive FDG PET/CT Images	8
Bone SPECT/CT in the Evaluation of Painful Total Ankle Replacement	8
Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters	8
Dermatomyositis on 68Ga-FAPI PET/CT in a Patient With Nasopharyngeal Carcinoma	8
Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non–Small Cell Lung Cancer	8
Locoregional Treatment of Glioblastoma With Targeted α Therapy	8
PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma	8
Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA	8
Mesenteric Inflammatory Myofibroblastic Tumor on 68Ga-FAPI PET/CT	8
Nocardia Infection With Adrenal Gland Abscess Mimicking Metastatic Lung Cancer on FDG PET/CT	8
Role of Dynamic Parameters of 18F-DOPA PET/CT in Pediatric Gliomas	8
COVID-19 Vaccine–Induced Multisystem Inflammatory Syndrome With Polyserositis Detected by FDG PET/CT	8
An Intravenous 100-mL Lipid Emulsion Infusion Dramatically Improves Myocardial Glucose Metabolism Extinction in Cardiac FDG PET Clinical Practice	8
18F-FDG PET/CT Imaging of Testicular Myeloid Sarcoma in a Pediatric Patient	8
18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient	8
Machine Learning Quantitative Analysis of FDG PET Images of Medial Temporal Lobe Epilepsy Patients	8
A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer	8
Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination	8
Resolution of Misleading COVID-19 Vaccination–Related Nodal and Splenic FDG Uptake in the Follow-up Study	8
68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes	8
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in Dermatofibrosarcoma Protuberans	8
Elevated 68Ga-FAPI Uptake by Primary Benign Intraosseous Meningioma	7
FDG-Avid Pulmonary Nodules and Tracheobronchial Mural Inflammation in IgG4-Related Disease	7
Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2	7
False-Positive 18F–Prostate-Specific Membrane Antigen–1007 PET/CT Caused by Hepatic Multifocal Inflammatory Foci	7
Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome	7
Uncovering an Optic Nerve Sheath Meningioma Using 68Ga-DOTATATE PET/CT	7
Supraclavicular and Axillary Lymphadenopathy Induced by COVID-19 Vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT	7
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients	7
177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases	7
68Ga-FAPI PET/CT Imaging of Intracranial Syphilitic Gumma	7
18F-FDG and 68Ga-FAPI PET/CT in the Evaluation of Ground-Glass Opacity Nodule	7
Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor–Positive Breast Cancer	7
Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging?	7
Cerebral Venous Sinus Thrombosis Caused by Neuro-Behçet Disease Accidentally Detected by 68Ga-FAPI PET/CT	7
High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data	7
68Ga-DOTA-FAPI-04 Uptake of Accessory Breast in a Patient With Breast Cancer	7
Rare Brain Metastasis in Parotid Adenoid Cystic Carcinoma Detected on 68Ga-PSMA PET/CT	7
Delayed [18F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis	7
Elevated 68Ga-FAPI Activity in the Plasmacytoma of the Ribs	7
68Ga-FAPI PET/CT Provides a Clear Picture of a Klatskin Tumor That 18F-FDG PET/CT Missed	7
18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT Findings of Abdominal Leiomyosarcoma	7
Machine Learning Model to Predict Diagnosis of Mild Cognitive Impairment by Using Radiomic and Amyloid Brain PET	7
68Ga-FAPI PET/CT Imaging	7
COVID-19 Vaccination Manifesting as Unilateral Lymphadenopathies Detected by 18F-Choline PET/CT	7
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis	7
68Ga-FAPI PET/CT Detected Non–FDG-Avid Gastric Stromal Tumor	7
Lipid-Poor Renal Angiomyolipoma Mimicking Renal Cell Carcinoma on 68Ga-FAPI-04 PET/CT	7
68Ga-PSMA-11 and 18F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate	7
68Ga-PSMA PET/CT to Distinguish Brain Metastasis of Renal Cell Carcinoma From Radiation Necrosis After Stereotactic Radiosurgery	7
Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT	7
123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer	7
Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis	7
Prospective Paired Comparison of 123I-FP-CIT SPECT Images Obtained With a 360°-CZT and a Conventional Camera	7
DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT	7
Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints	7
Glioblastoma Recurrence Versus Radiotherapy Injury	7
68Ga-FAPI PET/CT Imaging of Multiple Muscle Metastases of Pancreatic Cancer	7
Elevated 123I-MIBG Activity in Intramuscular Hemangioma	6
Application of Multimodal Imaging Biomarker in the Differential Diagnosis of Ovarian Mass	6
Features of Systemic Immune Response From COVID-19 Vaccination on 18F-FDG PET/CT	6
Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET	6
The Association of Tumor Burden by 18F-FDG PET/CT and Survival in Vulvar Carcinoma	6
Incidental Detection of Sinonasal Inverted Papilloma With 68Ga-FAPI PET/CT in a Patient With Esophageal Cancer	6
124I-PET/CT–Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas	6
Posttraumatic Scab on 131I Whole-Body Scan—A False-Positive Finding	6
Reversing “Flip-Flop” Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib	6
Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease	6
Utility of 18F–Prostate-Specific Membrane Antigen 1007 in Imaging of Tumor Thrombus of Renal Cell Carcinoma	6
Xanthogranulomatous Cholecystitis Masquerading as Gallbladder Carcinoma on 68Ga-FAPI-04 PET	6
Incidental Detection of Sacral Insufficiency Fracture on 68Ga-FAPI PET/MR	6
Increased FAPI Activity in Pulmonary Tuberculosis	6
A New Radiopharmaceutical 225Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases	6
18F-FDG and 68Ga-FAPI-04 in the Evaluation of Aggressive Perivascular Epithelioid Cell Tumor	6
Quality and Safety in Healthcare, Part XC	6
18F-FDG Versus 68Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	6
18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients	6